Eschler Asset Management LLP Invests $794,000 in Krystal Biotech, Inc. $KRYS

Key Points

• Eschler Asset Management LLP purchased 4,403 shares of Krystal Biotech, Inc. for approximately $794,000, making it the firm's 20th largest holding.
• Institutions own 86.29% of Krystal Biotech's stock, with several hedge funds significantly increasing their stakes in the fourth quarter.
• Analysts generally maintain a "buy" rating for Krystal Biotech, with a consensus target price of $210.38, reflecting positive sentiment in the market despite various price adjustments.

Eschler Asset Management LLP bought a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 4,403 shares of the company's stock, valued at approximately $794,000. Krystal Biotech comprises 2.0% of Eschler Asset Management LLP's holdings, making the stock its 20th biggest position.

Other hedge funds also recently bought and sold shares of the company. Crossmark Global Holdings Inc. lifted its stake in shares of Krystal Biotech by 2.7% in the first quarter. Crossmark Global Holdings Inc. now owns 2,370 shares of the company's stock valued at $427,000 after buying an additional 63 shares during the period. Xponance Inc. lifted its stake in shares of Krystal Biotech by 4.9% in the first quarter. Xponance Inc. now owns 1,873 shares of the company's stock valued at $338,000 after buying an additional 88 shares during the period. Sound View Wealth Advisors Group LLC lifted its stake in shares of Krystal Biotech by 6.7% in the first quarter. Sound View Wealth Advisors Group LLC now owns 1,515 shares of the company's stock valued at $273,000 after buying an additional 95 shares during the period. New York State Teachers Retirement System lifted its stake in shares of Krystal Biotech by 0.6% in the first quarter. New York State Teachers Retirement System now owns 15,979 shares of the company's stock valued at $2,881,000 after buying an additional 100 shares during the period. Finally, Fifth Third Bancorp lifted its stake in shares of Krystal Biotech by 159.1% in the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock valued at $31,000 after buying an additional 105 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS traded down $5.07 during mid-day trading on Monday, hitting $145.20. 321,594 shares of the stock were exchanged, compared to its average volume of 327,462. The company has a market cap of $4.20 billion, a P/E ratio of 29.51 and a beta of 0.66. The stock's fifty day simple moving average is $146.65 and its two-hundred day simple moving average is $153.79. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, beating analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The business had revenue of $96.04 million during the quarter, compared to analyst estimates of $95.42 million. As a group, equities research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 13,435 shares of Krystal Biotech stock in a transaction on Monday, July 14th. The shares were sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the transaction, the insider directly owned 1,443,276 shares of the company's stock, valued at $216,924,382.80. This trade represents a 0.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 49,800 shares of company stock worth $7,487,943 over the last quarter. Company insiders own 13.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on KRYS shares. Bank of America cut their price target on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. Chardan Capital cut their price target on shares of Krystal Biotech from $219.00 to $216.00 and set a "buy" rating for the company in a research note on Friday, August 22nd. Citigroup restated a "neutral" rating and set a $166.00 price target (down previously from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Finally, HC Wainwright restated a "buy" rating and set a $240.00 price target on shares of Krystal Biotech in a research note on Friday, August 22nd. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $210.38.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).